Enanta Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US29251M1062

SecurityENTA / Enanta Pharmaceuticals, Inc.
InstitutionSei Investments Co
Latest Disclosed Ownership98,782 shares
Latest Disclosed Value $ 1,557,795
Sei Investments Co reports 33.75% increase in ownership of ENTA / Enanta Pharmaceuticals, Inc.

On February 13, 2026 - Sei Investments Co filed a 13F-HR form disclosing ownership of 98,782 shares of Enanta Pharmaceuticals, Inc. (US:ENTA) valued at $1,557,792 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 73,853 shares of Enanta Pharmaceuticals, Inc.. This represents a change in shares of 33.75% during the quarter. The current value of the position is $1,158,713 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 98,782 24,929 33.75 1,558 76.13 0.0015
2025-11-13 2025-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 73,853 0 0.00 884 58.42 0.0010
2025-08-14 2025-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 73,853 0 0.00 558 37.10 0.0006
2025-05-14 2025-03-31 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 73,853 1,064 1.46 408 -2.63 0.0005
2025-05-13 2025-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 72,789 0 419 0.0005
2025-02-11 2024-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 72,789 -136 -0.19 419 -44.64 0.0005
2024-11-12 2024-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 72,925 0 0.00 756 -20.11 0.0010
2024-08-13 2024-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 72,925 -15,230 -17.28 946 -38.60 0.0013
2024-05-07 2024-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 88,155 0 0.00 1,539 85.65 0.0023
2024-02-14 2023-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 88,155 40,276 84.12 830 55.24 0.0013
2023-11-14 2023-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 47,879 47,879 535 0.0010
2022-11-14 2022-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 0 -13,942 -100.00 0 -100.00
2022-08-15 2022-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 13,942 -4,628 -24.92 659 -50.19 0.0014
2022-05-13 2022-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 18,570 -9,186 -33.10 1,323 -35.81 0.0027
2022-02-14 2021-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 27,756 8,178 41.77 2,061 87.53 0.0039
2021-11-12 2021-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 19,578 3 0.02 1,099 30.68 0.0023
2021-08-06 2021-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 19,575 -242 -1.22 841 -10.82 0.0019
2021-05-12 2021-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 19,817 -148 -0.74 943 15.71 0.0024
2021-02-08 2020-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 19,965 -1,010 -4.82 815 -13.02 0.0021
2020-12-04 2020-09-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 20,975 1,753 9.12 937 -2.19 0.0027
2020-11-06 2020-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 20,983 1,761 937 2,256.0877
2020-08-17 2020-06-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 19,222 1,844 10.61 958 7.16 0.0030
2020-08-11 2020-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 20,820 3,442 1,277 3,463.9305
2020-05-14 2020-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 17,378 -3,261 -15.80 894 -29.88 0.0033
2020-02-06 2019-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 20,639 0 0.00 1,275 2.82 0.0038
2019-11-12 2019-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 20,639 0 0.00 1,240 -28.82 0.0032
2019-08-14 2019-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 20,639 0 0.00 1,742 -11.62 0.0057
2019-05-15 2019-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 20,639 4,679 29.32 1,971 48.42 0.0066
2019-02-13 2018-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 15,960 232 1.48 1,328 0.53 0.0047
2018-11-08 2018-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 15,728 13,460 593.47 1,321 402.28 0.0048
2018-08-03 2018-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 2,268 346 18.00 263 68.59 0.0009
2018-05-11 2018-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 1,922 1,919 63,966.67 156 0.0006
2018-02-08 2017-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 3 3 0 0.0000
2016-05-10 2016-03-31 13F/A-1 DIREXION SHS ETF TR COM 29251M106 0 0 0 0.0000
2016-02-03 2015-12-31 13F DIREXION SHS ETF TR COM 29251M106 0 -10,024 -100.00 0 -100.00
2015-11-02 2015-09-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 10,024 10,024 362 0.0033
2015-10-30 2015-09-30 13F DIREXION SHS ETF TR COM 29251M106 10,024 363
2015-05-01 2015-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 0 -111 -100.00 0 -100.00
2015-02-10 2014-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 111 111 6 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.